Hope S Rugo1, Florence Lerebours2, Eva Ciruelos3, Pamela Drullinsky4, Manuel Ruiz-Borrego5, Patrick Neven6, Yeon Hee Park7, Aleix Prat8, Thomas Bachelot9, Dejan Juric10, Nicholas Turner11, Nickolas Sophos12, Juan Pablo Zarate12, Christina Arce12, Yu-Ming Shen13, Stuart Turner12, Hemanth Kanakamedala14, Wei-Chun Hsu15, Stephen Chia16. 1. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Hope.Rugo@ucsf.edu. 2. Institut Curie, Saint-Cloud, France. 3. Medical Oncology Department, Breast Cancer Unit, University Hospital 12 de Octubre, Madrid, Spain. 4. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Oncology, Hospital Virgen del Rocío de Sevilla, Seville, Spain. 6. University Hospital Leuven Breast Centre, Leuven, Belgium. 7. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 8. Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain. 9. Medical Oncology Department, Centre Léon Bérard, Lyon, France. 10. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. 11. Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK. 12. Global Medical Affairs, Oncology, Novartis, East Hanover, NJ, USA. 13. Global Medical Affairs, Biostatistics, Novartis, Munich, Germany. 14. Department of Evidence Strategy, Genesis Research, Hoboken, NJ, USA. 15. RWE Analytics, Genesis Research, Hoboken, NJ, USA. 16. British Columbia Cancer Agency, Vancouver, BC, Canada.
Abstract
BACKGROUND: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A. METHODS: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide. Participants aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 2 or less, with no more than two previous anticancer treatments and no more than one previous chemotherapy regimen, were enrolled in three cohorts. In cohort A, patients must have had progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor as the immediate previous treatment. Patients received oral alpelisib 300 mg/day (continuously) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1. The primary endpoint was the proportion of patients alive without disease progression at 6 months per local assessment using Response Evaluation Criteria in Solid Tumors, version 1.1, in patients with a centrally confirmed PIK3CA mutation. This trial is registered with ClinicalTrials.gov, NCT03056755. FINDINGS: Between Aug 14, 2017, and Dec 17, 2019 (data cutoff), 127 patients with at least 6 months' follow-up were enrolled into cohort A. 121 patients had a centrally confirmed PIK3CA mutation. At data cutoff, median follow-up was 11·7 months (IQR 8·5-15·9). 61 (50·4%; 95% CI 41·2-59·6) of 121 patients were alive without disease progression at 6 months. The most frequent grade 3 or worse adverse events were hyperglycaemia (36 [28%] of 127 patients), rash (12 [9%]), and rash maculopapular (12 [9%]). Serious adverse events occurred in 33 (26%) of 127 patients. No treatment-related deaths were reported. INTERPRETATION: BYLieve showed activity of alpelisib plus fulvestrant with manageable toxicity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a CDK4/6 inhibitor plus an aromatase inhibitor. FUNDING: Novartis Pharmaceuticals.
BACKGROUND:Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A. METHODS: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumourPIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide. Participants aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 2 or less, with no more than two previous anticancer treatments and no more than one previous chemotherapy regimen, were enrolled in three cohorts. In cohort A, patients must have had progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor as the immediate previous treatment. Patients received oral alpelisib 300 mg/day (continuously) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1. The primary endpoint was the proportion of patients alive without disease progression at 6 months per local assessment using Response Evaluation Criteria in Solid Tumors, version 1.1, in patients with a centrally confirmed PIK3CA mutation. This trial is registered with ClinicalTrials.gov, NCT03056755. FINDINGS: Between Aug 14, 2017, and Dec 17, 2019 (data cutoff), 127 patients with at least 6 months' follow-up were enrolled into cohort A. 121 patients had a centrally confirmed PIK3CA mutation. At data cutoff, median follow-up was 11·7 months (IQR 8·5-15·9). 61 (50·4%; 95% CI 41·2-59·6) of 121 patients were alive without disease progression at 6 months. The most frequent grade 3 or worse adverse events were hyperglycaemia (36 [28%] of 127 patients), rash (12 [9%]), and rash maculopapular (12 [9%]). Serious adverse events occurred in 33 (26%) of 127 patients. No treatment-related deaths were reported. INTERPRETATION: BYLieve showed activity of alpelisib plusfulvestrant with manageable toxicity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a CDK4/6 inhibitor plus an aromatase inhibitor. FUNDING: Novartis Pharmaceuticals.
Authors: Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: Diana Lüftner; Peter A Fasching; Renate Haidinger; Nadia Harbeck; Christian Jackisch; Volkmar Müller; Eva Schumacher-Wulf; Christoph Thomssen; Michael Untch; Rachel Würstlein Journal: Breast Care (Basel) Date: 2022-01-20 Impact factor: 2.860
Authors: Maria I Stamou; Christopher Chen; Seth A Wander; Jeffrey G Supko; Dejan Juric; Aditya Bardia; Deborah J Wexler Journal: JCO Precis Oncol Date: 2022-06
Authors: Grace M Choong; Savannah Liddell; Roberto A Leon Ferre; Ciara C O'Sullivan; Kathryn J Ruddy; Tufia C Haddad; Timothy J Hobday; Prema P Peethambaram; Minetta C Liu; Matthew P Goetz; Karthik V Giridhar Journal: Breast Cancer Res Treat Date: 2022-08-31 Impact factor: 4.624
Authors: Stuart Turner; Stephen Chia; Hemanth Kanakamedala; Wei-Chun Hsu; Jinhee Park; David Chandiwana; Antonia Ridolfi; Chu-Ling Yu; Juan Pablo Zarate; Hope S Rugo Journal: Oncologist Date: 2021-05-13
Authors: Harold J Burstein; Mark R Somerfield; Debra L Barton; Ali Dorris; Lesley J Fallowfield; Dharamvir Jain; Stephen R D Johnston; Larissa A Korde; Jennifer K Litton; Erin R Macrae; Lindsay L Peterson; Praveen Vikas; Rachel L Yung; Hope S Rugo Journal: J Clin Oncol Date: 2021-07-29 Impact factor: 44.544